(We are targeting applicants of all genders)
Full time | limited unlimited to 2 years | Announcement number: 185-2025
The Department of Hematology and Oncology at the University Hospital Frankfurt provides a comprehensive range of diagnostic and therapeutic services for patients with solid tumors and malignancies of the hematopoietic system. Within this scientific environment, the research group led by Prof. Dr. med. Thomas Oellerich focuses on uncovering oncogenic signaling pathways, regulators of tumor viability, and mechanisms of resistance to therapies, with a primary emphasis on acute myeloid leukemia (AML) and aggressive lymphomas.
For details, visit https://lymphoma-leukemia-research-frankfurt.de or refer to key publications, including:
• Phelan, Scheich et al., Cancer Cell (2024)
• Jayavelu, Wolf, Buettner et al., Cancer Cell (2022)
• Mohr et al., Cancer Cell (2017)
• Schneider, Oellerich et al., Nature Medicine (2017)
• Phelan et al., Nature (2018)
The Oellerich Lab leverages cutting-edge proteogenomics and functional genomics to explore the molecular underpinnings of hematological cancers. The laboratory is part of the Frankfurt Cancer Institute (FCI) and the German Consortium for Translational Cancer Research (DKTK), supported by the research infrastructure of the University Hospital Frankfurt and the Georg-Speyer-Haus. Strategic collaborations with international institutions, including the NIH and the Dana-Farber Cancer Center, further enhance the lab's global impact.
The lab is seeking a motivated postdoctoral researcher to join a project funded by the German Cancer Aid (Deutsche Krebshilfe). The role focuses on elucidating molecular mechanisms of oncogenesis and therapy resistance in AML. The candidate will develop multiplexed, high-throughput functional genomic screens to dissect the roles of oncogenic drivers and resistance pathways.
The lab employs a wide array of experimental techniques, including:
• Single-cell CRISPR/Cas9 screening technologies
• Quantitative (phospho-)proteomics
• Next-generation sequencing (NGS) and single-cell RNA sequencing
• Fluorescence-activated cell sorting (FACS) and advanced flow cytometry
• High-resolution imaging technologies, such as proximity ligation assays (PLAs) and super-resolution microscopy
• Computational biology
For an insight into the University Hospital Frankfurt, click here.